These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30638432)

  • 1. Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension.
    Sulica R; Sangli S; Chakravarti A; Steiger D
    Pulm Circ; 2019; 9(1):2045894019826944. PubMed ID: 30638432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.
    Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
    Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China.
    Chen YC; Dai HL; Liu CL; Li J; Ji QS; Cao YS; Xiao J; Jian R; Zhuo JM; Luo XC; Gu H
    Curr Med Res Opin; 2024 Jul; ():1-15. PubMed ID: 39044676
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.
    Schweintzger S; Koestenberger M; Schlagenhauf A; Grangl G; Burmas A; Kurath-Koller S; Pocivalnik M; Sallmon H; Baumgartner D; Hansmann G; Gamillscheg A
    Cardiovasc Diagn Ther; 2020 Oct; 10(5):1675-1685. PubMed ID: 33224780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
    Channick R; Chin KM; McLaughlin VV; Lammi MR; Zamanian RT; Turricchia S; Ong R; Mitchell L; Kim NH
    Cardiol Ther; 2024 Jun; 13(2):315-339. PubMed ID: 38451426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up.
    Jariwala P; Maturu VN; Jadhav KP; Punjani A; Boorugu H
    Lung India; 2022; 39(1):12-15. PubMed ID: 34975047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of prognosis and associated risk factors in pediatric idiopathic pulmonary arterial hypertension].
    Liu Q; Zhang C; Li QQ; Zhu Y; Zhang D; Zhao WG; Gu H
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):23-28. PubMed ID: 29342993
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study.
    Yang S; Yang Y; Zhang Y; Kuang T; Gong J; Li J; Li Y; Wang J; Guo X; Miao R
    ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34513985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study.
    Sood N; Aranda A; Platt D; LaRose A; Kleinjung F; O'Brien G
    Pulm Circ; 2019; 9(1):2045894018823715. PubMed ID: 30574833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.